About the Authors
- Hatem A. Elshabrawy
-
Affiliation Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America
- Melissa M. Coughlin
-
Affiliation Centers for Disease Control and Prevention, Measles, Mumps, Rubella and Herpes Virus Laboratory Branch, Atlanta, Georgia, United States of America
- Susan C. Baker
-
Affiliation Department of Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States of America
- Bellur S. Prabhakar
-
* E-mail: bprabhak@uic.edu
Affiliation Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America
Competing Interests
The authors did not receive any funding or support from Amgen British Columbia Incorporation. Since the authors had helped identify and characterize SARS-CoV neutralizing antibodies, the authors are listed as co-inventors on a patent that is owned by the company. The authors were neither paid for, nor will receive any income from, this work. This does not alter the authors’ adherence to all PLOS ONE policies on sharing data, and materials upon completion of MTA with Amgen. The authors are acknowledging the company for providing the HmAbs and hybridomas used for studies reported in the manuscript. The authors have no financial or competing interest.
Author Contributions
Conceived and designed the experiments: HAE BSP. Performed the experiments: HAE. Analyzed the data: HAE BSP. Contributed reagents/materials/analysis tools: MMC. Wrote the paper: HAE BSP. Revised the manuscript: MMC SCB.